ENTITY
SciClone Pharmaceuticals

SciClone Pharmaceuticals (SCICLONE HK)

108
Analysis
Health Care • China
SciClone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for oncology and severe infection in Mainland China and internationally. Its portfolio includes proprietary product Zadaxin, used for hepatitis B, hepatitis C, and certain cancers, as well as in-licensed products like Zometa, DANYELZA, and Angiomax. The company was founded in 1990 and is headquartered in Shanghai, China.
more
•23 May 2024 14:40

Henlius Biotech (2696 HK): Fosun Offer?

IF Fosun wants to take the company private, an Offer Price of $26/share, may get the job done. $30/share would be optically be more preferable.

Logo
485 Views
Share
•20 May 2024 00:15

Merger Arb Mondays (20 May) - L'Occitane, China TCM, SciClone, Malaysia Airports, I'rom, Hollysys

This week, the highest gross spreads are HEC Pharma (84.7%), Hollysys (16.5%), QV Equities (9.1%), Ansarada (8.7%), Malaysia Airports (8.3%), China...

Logo
637 Views
Share
•19 May 2024 10:05

Hong Kong Connect Flows (May 17th): BOC, Sinopec, CNOOC, HSBC, Kuaishou Technology, Tencent

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for BOC, Sinopec, CNOOC, HSBC, Kuaishou Technology, Tencent.

Logo
559 Views
Share
•19 May 2024 07:00

Last Week in Event SPACE: Japan Post, Great Eastern, Malaysia Airports, L'Occitane

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

Logo
780 Views
Share
bullish•ESR
•18 May 2024 15:00

(Mostly) Asia-Pac M&A: ESR Group, I'Rom Group, S Line, Huafa Property Services, Kansai Super Market

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
809 Views
Share
x